---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-001490"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2024-01-04T23:59:59+00:00"
generated_at: "2026-06-07T04:06:08.567355+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Adicet Bio gets FDA IND clearance for ADI-001 in lupus nephritis; plans Phase 1 in Q2 2024

## Summary
- FDA cleared IND for ADI-001 in lupus nephritis Dec 2023; Phase 1 start planned Q2 2024.
- Focusing ADI-001 Phase 1 GLEAN enrollment on MCL patients; June 2023 data showed 80% CR rate.
- ADI-001 clinical update expected 2H 2024; evaluating accelerated approval pathway for MCL.
- ADI-270 IND submission for renal cell carcinoma planned Q2 2024 after positive pre-IND meeting.
- Cash and equivalents expected to fund operations into second half of 2025.

## SEC filing metadata
- accession: 0000950170-24-001490
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2024-01-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000095017024001490/0000950170-24-001490-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000095017024001490/acet-20240104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-001490
- JSON: https://secwatch.observer/filing/0000950170-24-001490.json
- Plain text: https://secwatch.observer/filing/0000950170-24-001490.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.